SCHEMBL701147

SCHEMBL701147

CC(=O)Oc1ccncc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.58
HSD17B10 Q99714 3/20 0.54
MAPT P10636 3/20 0.52
POLB P06746 1/20 0.52
PKM P14618 1/20 0.52
CYP2C9 P11712 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
ELANE P08246 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C19 P33261 1/20 0.50
ALDH1A1 P00352 1/20 0.47
HSP90AA1 P07900 1/20 0.47
GAA P10253 1/20 0.47
KMT2A Q03164 5/20 0.46
CYP3A4 P08684 3/20 0.46
KDM4E B2RXH2 2/20 0.46
ESR1 P03372 2/20 0.46
SLC6A3 Q01959 2/20 0.46
ABCB11 O95342 1/20 0.46
ADRA2A P08913 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27539616 0.98 LMNA (0.56) LMNAHSD17B10MAPTPOLBPKM
Hydrochloric Acid SCHEMBL2327786 0.98 LMNA (0.56) LMNAHSD17B10MAPTPOLBPKM
SCHEMBL380364 0.83 HSD17B10 (0.56) LMNAHSD17B10MAPTCYP2C9SMN1; SMN2
SCHEMBL7781973 0.82 HSD17B10 (0.50) LMNAHSD17B10MAPTPOLBCYP2C9
SCHEMBL269329 0.82 LMNA (0.80) LMNAHSD17B10MAPTPOLBPKM
SCHEMBL2625475 0.80 ELANE (0.60) LMNAHSD17B10CYP2C9SMN1; SMN2ELANE
SCHEMBL18727667 0.80 HSD17B10 (0.58) LMNAHSD17B10CYP2C9SMN1; SMN2CYP1A2
Lithium SCHEMBL30522746 0.79 LMNA (0.76) LMNAHSD17B10MAPTPOLBPKM
SCHEMBL14760365 0.79 LMNA (0.76) LMNAHSD17B10MAPTPOLBPKM
SCHEMBL7268906 0.79 ELANE (0.54) LMNAHSD17B10MAPTPOLBCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025243208-A2 PROCESS FOR THE PREPARATION AND/OR PURIFICATION OF POLYETHYLENE GLYCOL AND ITS DERIVATIVES, OBTAINED PRODUCT AND USES THEREOF HOVIONE - FARMACIÊNCIA, SA (PT) 2025-11-27 WO claimed
CN-114163456-B Phenothiazine coumarin-based pyridine salt compound and preparation and application thereof 西南医科大学附属医院 2023-08-22 CN claimed
CN-105130886-A Preparation method for 4-fluoro-3-methyl-methyl pyridine-2-carboxylate UNIV HENAN NORMAL 2015-12-09 CN claimed
CN-102199120-A Method for synthesizing 2,2'-bipyridine-4,4'-dicarboxylic acid UNIV LIAOCHENG 2011-09-28 CN claimed
CN-101709472-A Preparation method of substituted pyridine carbonylhydrazone metal corrosion inhibitor UNIV GUILIN TECH GUT 2010-05-19 CN claimed
WO-2025243208-A2 PROCESS FOR THE PREPARATION AND/OR PURIFICATION OF POLYETHYLENE GLYCOL AND ITS DERIVATIVES, OBTAINED PRODUCT AND USES THEREOF HOVIONE - FARMACIÊNCIA, SA (PT) 2025-11-27 WO disclosed
US-11834416-B2 Cleavable agents BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY (US) 2023-12-05 US disclosed
US-11834416-B2 Cleavable agents BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY (US) 2023-12-05 US disclosed
CN-110312533-B Prodrugs of cytotoxic active agents having enzymatically cleavable groups 拜耳公司 2023-11-03 CN disclosed
EP-3647311-B1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF BEIJING TIDE PHARMACEUTICAL CO LTD (CN) 2023-11-01 EP disclosed
CN-114163456-B Phenothiazine coumarin-based pyridine salt compound and preparation and application thereof 西南医科大学附属医院 2023-08-22 CN disclosed
US-20230202981-A1 NOVEL SMALL MOLECULES FOR TARGETED DEGRADATION OF UNTARGETABLE KRAS IN CANCER THERAPY PILLAI UNIVERSAL LLC 2023-06-29 US disclosed
US-4510138-A 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]cephalosporin derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1985-04-09 US disclosed
US-4349552-A TREATMENT OF CANCER FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1982-09-14 US disclosed
EP-0010941-B1 5-FLUOROURACIL DERIVATIVES, PREPARATION THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-05-12 EP disclosed
US-4278671-A ANTIBIOTICS, BACTERICIDES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1981-07-14 US disclosed
EP-0010941-A1 5-Fluorouracil derivatives, preparation thereof and their pharmaceutical compositions FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-05-14 EP disclosed
US-4182866-A CEPHALOSPORINS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1980-01-08 US disclosed
US-4145540-A ANTIBIOTICS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1979-03-20 US disclosed
US-4011214-A 3-(MORPHOLINOALKOXYIMINOMETHYL)CEPHEM COMPOUNDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1977-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202981-A1 NOVEL SMALL MOLECULES FOR TARGETED DEGRADATION OF UNTARGETABLE KRAS IN CANCER THERAPY KRAS, HRAS, NRAS LMNA 4288/4885HSD17B10 2892/4885MAPT 1580/4885
US-11834416-B2 Cleavable agents LGMN, CTSL, GZMB LMNA 174/4885HSD17B10 3457/4885MAPT 3956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.